BioNTech Shares Fall 6% After BNT113 Trial Misses Key Endpoint

Enna Lee

1 min read

Add as a preferred source on Google

BioNTech Shares Fall 6% After BNT113 Trial Misses Key Endpoint

The Phase 2/3 trial did not meet one of its dual primary endpoints, progression-free survival.

By Enna Lee

Published Oct 13, 2026, 11:48 AM EDT

Unlabeled clinical vial beside a microscope in a quiet laboratory / TokenPost.ai

BioNTech shares fell about 6% in Tuesday trading after a Phase 2/3 trial of its BNT113 cancer therapy failed to meet one of its dual primary endpoints.

The missed endpoint was progression-free survival.

Enna Lee

Reporter

Enna Lee reports on investing and digital-asset markets for TokenPost. Send corrections or tips to info@tokenpost.com.